30 closest matches · ranked by relevance
Metastatic Solid Tumors
Primary: Count of Participants With NRTK Fusions Among Participants Analyzed by NGS (Next-generation Sequencing). — 11 Participants
Locally Advanced or Metastatic Infantile Fibrosarcoma Harboring an NTRK Gene Fusion · Infantile Fibrosarcoma
Primary: Time to Medical Treatment Failure — NA; NA; NA; 24.0 months — p=0.0058
Neuroblastoma
Primary: MTD/RP2D Determination A1 — 0; 0; 0; 0 Participants
Solid Neoplasms With NTRK Fusions
Primary: Duration of Response (DoR) — 24.5 months
Advanced Malignant Solid Neoplasm · Cholangiocarcinoma · Metastatic Malignant Solid Neoplasm
Primary: Overall Response Rate (ORR) — 13.3 percentage of participants
Cancer
Primary: Incidence of Treatment Emergent Adverse Events in Subjects Treated With Trametinib Monotherapy — 3; 19; 12; 16 Participants
Advanced Malignant Solid Neoplasm · Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma · Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
Primary: Response Rate — 0 Percentage of patients
Neurofibromatosis Type 1 · Plexiform Neurofibroma
Primary: Change From Baseline Target Tumor Volume at 12 Months — 27; 17 Participants
Recurrent Childhood Anaplastic Large Cell Lymphoma · Recurrent Malignant Solid Neoplasm · Recurrent Neuroblastoma
Primary: Maximum-tolerated Dose and Recommended Phase 2 Dose of Crizotinib — 280 mg/m²/dose BID
Neurofibromatosis 1 · Neurofibroma, Plexiform
Primary: Median Time to Disease Progression — 13.2 Months
Neuroblastoma
Primary: Overall Response Rate [Complete Response + Very Good Partial Response + Partial Response (CR + VGPR + PR)] — 42 Participants
Neurofibromatosis 2 · Progressive Vestibular Schwannoma (VS)
Primary: Volumetric Response Rate — 0; 9 Participants
Advanced Malignant Solid Neoplasm · Ann Arbor Stage III Non-Hodgkin Lymphoma · Ann Arbor Stage IV Non-Hodgkin Lymphoma
Primary: Objective Response Rate — 0 percentage of patients
Advanced Malignant Solid Neoplasm · Ann Arbor Stage III Hodgkin Lymphoma · Ann Arbor Stage III Non-Hodgkin Lymphoma
Primary: Objective Response Rate (ORR) — 5 Percentage of participants
NF1 · Neurofibromatosis · Plexiform Neurofibromas
Primary: The Change in Tumor Size Based on Radiographic Assessment — -15.7; -4.1 mm^3
Adult Synovial Sarcoma · Recurrent Adult Soft Tissue Sarcoma · Stage III Adult Soft Tissue Sarcoma
Primary: Response Rate (CR + PR) Assessed by RECIST 1.1 (Phase II) — 4; 1; 5; 0 participants
Malignant Peripheral Nerve Sheath Tumors · Neurofibromatosis 1
Primary: Clinical Benefit Rate of Selumetinib in Combination With Sirolimus in Patients With Unresectable or Metastatic NF1 Associated or Sporadic MPNST. — 0.095 Proportion
Previously Treated Childhood Rhabdomyosarcoma · Recurrent Childhood Rhabdomyosarcoma · Recurrent Childhood Soft Tissue Sarcoma
Primary: Response (Complete Response [CR] and Partial Response [PR]) — 1; 0; 0; 0 participants
Neuroblastoma · Medulloblastoma · Relapse
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 14 participants
Liposarcoma · Metastatic Liposarcoma
Primary: Number of Participants Who Were Progression Free — 12 Participants
Advanced Malignant Solid Neoplasm · Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma · Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
Primary: Objective Response Rate (ORR) — 25 percentage of participants
Adult Angiosarcoma · Adult Epithelioid Sarcoma · Adult Leiomyosarcoma
Primary: Overall Response Rate Measured by Complete Response (CR) Rate and Partial Response (PR) Rate as Determined by RECIST — 1; 0; 0; 0 participants
Recurrent Adult Soft Tissue Sarcoma · Stage III Adult Soft Tissue Sarcoma · Stage IV Adult Soft Tissue Sarcoma
Primary: Progression-free Survival — 1.8; 3.7 months
Gastrointestinal Stromal Tumors
Primary: Proportion of Participants With Best Overall Response at Month 6 (Core Phase) Determined According to the RECIST v1.0. — 0; 14; 21; 6 Participants
Glioblastoma Multiforme · Anaplastic Astrocytoma · Anaplastic Oligodendroglioma
Primary: Number of Patients Who Experienced Dose-limiting Toxicities (DLTs) — 3 Participants
Pleuropulmonary Blastoma · Recurrent Malignant Peripheral Nerve Sheath Tumor · Recurrent Neuroblastoma
Primary: Objective Response by Response Evaluation Criteria in Solid Tumors Version 1.1 — 0.00; 6.25; 0.00; 0.00 Percent of participants
Neuroblastoma
Primary: Percentage of Participants That Are Able to Meet Feasibility Parameters. — 100 percentage of participants
Non-Small Cell Lung Cancer
Primary: Overall Response Rate (ORR) by Investigator Assessment — 67.7 Percentage of participants
Advanced Malignant Solid Neoplasm · Recurrent Childhood Ependymoma · Recurrent Ewing Sarcoma
Primary: Objective Response Rate — 0 percentage of participants
Malignant Peripheral Nerve Sheath Tumors (MPNST) · Sarcoma
Primary: Number of Dose Limiting Toxicities of Ganetespib When Administered in Combination With Sirolimus. — 0; 1 DLTs